Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | PDE5A | O76074 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611433 | 0.90 | MAPK1 (0.53) | METAP1KMT2ATDP1L3MBTL1JAK2 | |
| SCHEMBL7605370 | 0.83 | MAPK1 (0.51) | METAP1KMT2ATDP1L3MBTL1JAK2 | |
| SCHEMBL7606590 | 0.83 | KDM4E (0.62) | KMT2AMEN1PDE5ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7605572 | 0.80 | GBA1 (0.67) | KMT2ATDP1L3MBTL1MEN1PDE5A | |
| SCHEMBL7613509 | 0.80 | METAP1 (0.67) | METAP1KMT2ATDP1L3MBTL1JAK2 | |
| SCHEMBL7610714 | 0.80 | METAP1 (0.67) | METAP1KMT2ATDP1L3MBTL1JAK2 | |
| SCHEMBL7605588 | 0.79 | GBA1 (0.75) | KMT2ATDP1L3MBTL1MEN1PDE5A | |
| SCHEMBL7606552 | 0.79 | MAPK1 (0.49) | KMT2AMEN1PDE5AALDH1A1LMNA | |
| SCHEMBL12674275 | 0.78 | METAP1 (1.00) | METAP1KMT2ATDP1L3MBTL1JAK2 | |
| SCHEMBL7610197 | 0.78 | METAP1 (0.64) | METAP1KMT2ATDP1L3MBTL1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | METAP1 1241/4885KMT2A 767/4885TDP1 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.